Agios Pharmaceuticals, Inc. (AGIO)
$30.21-1.98%Close
SELLRECOVERY · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.8B
- Beta
- 0.63
- P/E (TTM)
- -4.31
- Short % float
- 12.60%
- Days to cover
- 6.4
- SI change
- -7.2%
- 1W
- -4.76%
- 1M
- -9.06%
- vs SPY 1W
- -4.62%
- vs SPY 1M
- -11.57%
Industry peers
FMP comparable companies · ranked by market cap
- PTCTSELLPTC Therapeutics, Inc.$5.2BCRISISQ 18$62.56-4.77%
- MIRMSELLMirum Pharmaceuticals, Inc.$5.0BCRISISQ 36$81.35-7.48%
- IRONSELLDisc Medicine, Inc.$2.3BCRISISQ 0$60.77-6.42%
- BCRXSELLBioCryst Pharmaceuticals, Inc.$2.1BRECOVERYQ 6$8.29-3.47%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$15.29-2.48%
- PHARSELLPharming Group N.V.$675MCRISISQ -1$9.53-1.77%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AGIO?
- LOPJLB’s latest quantitative signal on Agios Pharmaceuticals, Inc. (AGIO) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AGIO in?
- Agios Pharmaceuticals, Inc. (AGIO) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Agios Pharmaceuticals, Inc. (AGIO) do?
- Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Addition…